Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Visualized Experiments : Jove|November 20, 2014
Real time analysis of metabolic profile in ex vivo mouse intestinal crypt organoid culturesTuba Bas, Leonard H Augenlicht
The Journal of Biological Chemistry|October 27, 2006
KCNE1 subunits require co-assembly with K+ channels for efficient trafficking and cell surface expressionKshama D Chandrasekhar, Tuba Bas, William R Kobertz
Journal of Cellular Physiology|February 7, 2015
Concise review: the role of oxygen in hematopoietic stem cell physiologyMojca Jež, Primož Rožman, Zoran Ivanović, et al.
Histochemistry and Cell Biology|October 16, 2012
The hazards of DAPI photoconversion: effects of dye, mounting media and fixative, and how to minimize the problemMojca Jež, Tuba Bas, Matija Veber, et al.
The Journal of Biological Chemistry|June 17, 2011
Post-translational N-glycosylation of type I transmembrane KCNE1 peptides: implications for membrane protein biogenesis and diseaseTuba Bas, Grace Y Gao, Anatoli Lvov, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 30, 2020
A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407Luis Paz-Ares, David Vicente, Ali Tafreshi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 10, 2020
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung CancerShirish Gadgeel, Delvys Rodríguez-Abreu, Giovanna Speranza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 2021
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced MelanomaJedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2022
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)Jeffrey S Weber, Dirk Schadendorf, Michele Del Vecchio, et al.
Pageof 1